K-pop

Alpha Drive One, the debut group of "Bopple 2," Releases New Album "Unbreakable: Boy Beast" Today

Features 7 tracks, including the title track "Born Day"

KIM HYUNSIK
2026-08-24 08:45:27
[Edaily Starin KIM HYUNSIK Reporter] Boy group Alpha Drive One (ALPHA DRIVE ONE) is set to make a comeback on the 24th with their new album "UNBREAKABLE: Boy BEAST."
(Photo courtesy of Wake One)
(Photo courtesy of Wake One)
ALPHA DRIVE ONE is the debut group from Mnet’s idol survival program “Boys 2 Planet.” They released their first mini-album, “EUPHORIA,” last January and began their official debut activities.
“Unbreakable: Boy Beast” is their second mini-album. The album features a total of seven tracks, including the title track “BORN DIRE,” as well as “Diamond Hour,” “One More Time,” “Talk to Me,” “OMG!,” “Good Life,” and “WELCOME home.”
Their agency, Wake One, explained, “This album explores the growing pains of youth as they navigate prejudice and stigma.”
The title track, “Born Day,” conveys the message, “I will keep racing forward without stopping, even amidst chaos.” It heightens tension and immersion with the raw textures of British rave and punk sounds.
All tracks and the title track’s music video will be released at 6:00 p.m. today via various online music platforms.
Wake One stated, “Alpha Drive One plans to heighten the immersive experience of the song with a ‘cinematic performance’ that stands out for its well-structured composition, reminiscent of watching a movie.”

Economy

Corporation

IT·Science

Economy

[VC's Pick] Riding the Wave of South Korea’s Defense Industry Boom, Digitron Sets Sights on IPO… Secures Pre-IPO Investment

This week (October 6–8), startups across various sectors—including defense, biotech, and artificial intelligence (AI) image-generation platforms—secured investments from venture capital (VC) firms and…
2026-10-09 11:11:03

Corporation

Plague Fears Boost Diagnostics; Peptron Plummets [K-bio pulse]

South Korean diagnostic stocks, including Humasis, GC Green Cross MS, and Genematrix, rallied on Tuesday as investors reacted to a suspected plague exposure incident at a Russian research institute.Th…
2026-10-09 08:01:04

IT·Science

Yuhan Reduces Overseas Clinical Trials for ‘Post-Lecraza’ from 6 to 2… Impact on U.S. Approval Strategy

Yuhan(000100)Overseas clinical trials for “YH32367” (nesprotamig), a bispecific antibody anticancer drug being developed by the company as a “post-Lecraza” (generic name: lazertinib) candidate, are be…
2026-10-09 07:31:03